Ask about this productRelated genes to: TARC antibody
- Gene:
- CCL17 NIH gene
- Name:
- C-C motif chemokine ligand 17
- Previous symbol:
- SCYA17
- Synonyms:
- TARC, ABCD-2
- Chromosome:
- 16q21
- Locus Type:
- gene with protein product
- Date approved:
- 1996-10-26
- Date modifiied:
- 2016-10-05
Related products to: TARC antibody
Related articles to: TARC antibody
- - Source: PubMed
Publication date: 2026/08/02
Zhang XinLi JiayanXu LuGuo XiaoqingEscames GermaineAcuña-Castroviejo DaríoZhao HuadongNi YunfengYang Yang - Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by keratinocyte hyperproliferation, altered differentiation, barrier dysfunction, and oxidative stress. Currently available therapies, including monoclonal antibodies and JAK inhibitors, have improved AD management but do not address all aspects of the disease, supporting the investigation of natural-product strategies as complementary approaches to long-term care. An acute in vitro model of canine atopic-like inflammation was established by exposing canine progenitor epidermal keratinocytes (CPEK) for 24 h to a defined cytokine cocktail (IFN-γ, IL-4, IL-13), followed by 24 h of treatment with hemp oil, blackcurrant seed oil, vitamin D, or their combination. Proliferation (Ki-67, cell-cycle), differentiation (KRT5, KRT10, TGM1, involucrin), tight-junction organization (CLDN1, TJP1, ZO-1, TEER), wound closure, nitrosative stress (3-nitrotyrosine), the NRF2/BACH1/HMOX1 axis, and the secretion of STAT1- and NF-κB-dependent inflammatory mediators (CXCL9, CXCL10, IL-8, IL-6) and the STAT6-targeted chemokine CCL17 were assessed. The cytokine cocktail induced a coherent AD-like phenotype: increased Ki-67, downregulated CLDN1, sustained nitrosative stress, NRF2 elevation paralleled by BACH1 induction, and robust secretion of STAT1- and NF-κB-dependent mediators. The four treatments modulated this phenotype according to clearly differential, pathway-specific profiles. Vitamin D, alone or combined, emerged as the most effective modulator of proliferation and acted preferentially on the downstream redox arm, inducing HMOX1 and reducing BACH1; both vitamin D-containing formulations exerted broad anti-inflammatory activity across the STAT1 and NF-κB axes. Hemp oil acted preferentially on tight-junction integrity (CLDN1 recovery), on the upstream NRF2 arm (NFE2L2 induction), on the STAT1 chemokine arm (CXCL9, CXCL10 reduction), and on wound closure. Blackcurrant seed oil acted preferentially on NF-κB-dependent IL-8 and on early wound-closure dynamics. This differential pharmacological footprint provides a rational basis for further investigation of these formulations as nutraceutical adjuncts in canine AD. - Source: PubMed
Tortolani DanielScipioni LuciaAnselmucci AlessandroCiaramellano FrancescaDi Leonardo MeriFusaro IsaOddi SergioGramenzi Alessandro - Topical postbiotic emollient (Strain CX) has shown efficacy for mild-to-moderate atopic dermatitis (AD) in a previous study; however, treatment responses according to allergic comorbidity status have not yet been explored. We conducted a analysis to evaluate the differential therapeutic effects of Strain CX in patients with AD stratified by the presence or absence of allergic comorbidities. This analysis was derived from a randomized, double-blind, vehicle-controlled trial (Clinical Research Information Service of South Korea, KCT0007876). A total of 98 patients with mild-to-moderate AD were stratified into placebo (n = 33), AD without allergic comorbidities (n = 29), and AD with allergic comorbidities (n = 36) groups. The primary outcomes were the Investigator's Global Assessment (IGA) score and the proportions of participants achieving 25% or 50% improvement in the Eczema Area and Severity Index (EASI), assessed at weeks 4 and 8. The secondary outcomes included a range of skin-related clinical and molecular measures, along with additional evaluations of serum inflammatory and allergic biomarkers as laboratory measures in the per-protocol analysis set. At week 8, 55.2% (16/29) of participants in the AD without allergic comorbidities group achieved an IGA score of 0 or 1 with ≥ 1 point reduction, compared to 30.6% (11/36) in the AD with allergic comorbidities group ( = 0.0272). Both Strain CX intervention groups showed significant improvements in skin parameters, including EASI, skin moisture, and transepidermal water loss. Notably, the AD with allergic comorbidities group solely exhibited significant reductions in systemic inflammatory markers, including sIL-2R (mean, -231.19; 95% confidence interval [CI], -378.82 to -83.57 pg/mL), CCL17 (-127.05; 95% CI, -251.80 to -2.31 pg/mL), and CCL22 (-578.40; 95% CI, -939.31 to -217.49 pg/mL). Clinical skin responses improved more in patients with AD without allergic comorbidities, while immunomodulatory benefits were observed in those with allergic comorbidities. These findings support patient stratification based on allergic comorbidity status for personalized Strain CX treatment strategies. Trial Registration: Clinical Research Information Service Identifier: KCT0007876. - Source: PubMed
Kang JiseungYim YesolLee HaeunKang So MinLee Dong-GeolHeo Young MokJo HyungwooKang SeunghyunKim Hyeon JinYon Dong KeonNehs Christa J - - Source: PubMed
Publication date: 2026/08/03
Su YihanWang TianyuLi LichenFang XiangTu XiaojiaoWang JianwenLiu YongxiaSun YonghuZhang Furen - Cyclopropanes are prevalent motifs in pharmaceuticals and natural products; however, the construction of complex cyclopropanes remains a longstanding issue owing to low intrinsic reactivity and steric congestion. Herein, we report a visible-light-mediated cyclopropanation of unactivated alkenes with diazo compounds an energy-transfer (EnT) pathway. This protocol provides direct access to a range of cyclopropanes, including spirocyclic, fused and those bearing quaternary carbon centers. Notably, a broad spectrum of unactivated alkenes-spanning endocyclic, bridged, polysubstituted, and terminal systems, along with diverse diazo reagents-are well tolerated, underscoring the generality of the method. The practicality is demonstrated by gram-scale synthesis and late-stage modification of natural products such as valencene, β-caryophyllene and flavanone. Moreover, in a preliminary assay, the caryophyllene oxide derivative exhibits promising anti-atopic dermatitis activity, showing nearly twice as high inhibition of CCL17 and CCL22 compared to its precursor, while exhibiting no detectable cytotoxicity. Finally, mechanistic studies support the involvement of triplet carbene species. These findings highlight the potential of this photochemical strategy for the rapid construction of challenging cyclopropanes and its utility in the development of bioactive natural product analogues. - Source: PubMed
Publication date: 2026/07/21
Zhang LeZhang NaWang DinggangYuan XiaoHan XinyuZhuo MiaomiaoGuo GuangyangZhang Wei-DongZhang HaoZhang Yu